Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05680922 · ClinicalTrials.gov registry record · Phase 1
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
A Phase 1 study of Large Cell Neuroendocrine Carcinoma of the Lung and Small Cell Lung Cancer Extensive Stage, sponsored by Legend Biotech USA.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT05680922: Recruiting Phase 1 study of Large Cell Neuroendocrine Carcinoma of the Lung and Small Cell Lung Cancer Extensive Stage, sponsored by Legend Biotech USA.
NCT05680922 is a Phase 1 study of Large Cell Neuroendocrine Carcinoma of the Lung and Small Cell Lung Cancer Extensive Stage that is actively recruiting participants, run by Legend Biotech USA. The registered enrollment target is 41 participants, below the 56-participant average among 4 other Large Cell Neuroendocrine Carcinoma of the Lung trials with a reported enrollment target (27% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05680922, a Phase 1 study of Large Cell Neuroendocrine Carcinoma of the Lung and Small Cell Lung Cancer Extensive Stage, is actively recruiting participants, sponsored by Legend Biotech USA.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Primary Outcome
Multiple doses will be tested to establish a recommended dose
Conditions Studied
Interventions
- BIOLOGICAL LB2102
Study Locations (4)
Florida
- Moffitt Cancer Center - Tampa
Kentucky
- University of Kentucky - Markey Cancer Center - Lexington
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
What NCT05680922 shows while recruiting
NCT05680922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 56-participant average among 4 other Large Cell Neuroendocrine Carcinoma of the Lung trials with a reported enrollment target (27% lower).
The record links to 2 conditions, with Large Cell Neuroendocrine Carcinoma of the Lung appearing as the primary indexed condition, and to 1 intervention - of which LB2102 is the first listed.
NCT05680922 reports a single indexed study location in Florida, Kentucky, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05680922 about?
NCT05680922 is a clinical study titled "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer". This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
What is the current status of trial NCT05680922?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-07-26. Estimated completion is 2028-03.
What conditions does trial NCT05680922 study?
This clinical trial studies the following conditions: Large Cell Neuroendocrine Carcinoma of the Lung, Small Cell Lung Cancer Extensive Stage.
What interventions are being tested in trial NCT05680922?
The interventions under investigation include: LB2102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05680922?
This trial is sponsored by Legend Biotech USA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05680922 being conducted?
This trial has 4 study locations across Florida, Kentucky, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large Cell Neuroendocrine Carcinoma of the Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RECRUITING · Phase 1
-
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
RECRUITING · Phase 1
-
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
RECRUITING · Phase 1
-
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI